Oxbow Advisors LLC Has $9.68 Million Stock Position in Bristol Myers Squibb Company $BMY

Oxbow Advisors LLC grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 24.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 179,524 shares of the biopharmaceutical company’s stock after purchasing an additional 35,740 shares during the quarter. Bristol Myers Squibb comprises about 0.8% of Oxbow Advisors LLC’s investment portfolio, making the stock its 25th biggest position. Oxbow Advisors LLC’s holdings in Bristol Myers Squibb were worth $9,684,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Physician Wealth Advisors Inc. boosted its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares in the last quarter. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $25,000. EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $32,000. Garner Asset Management Corp acquired a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $35,000. Finally, Beacon Financial Strategies CORP bought a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $38,000. 76.41% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Stock Down 0.3%

BMY stock opened at $56.10 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The company has a market cap of $114.56 billion, a PE ratio of 15.76, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The business’s 50-day simple moving average is $59.28 and its 200 day simple moving average is $54.91.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the firm posted $1.80 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.3 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.5%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald lifted their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, April 8th. HSBC raised their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Leerink Partners lifted their price objective on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.